Get started
GALAPAGOS
Long

Ready for Bulish

By RonaldoH64
FDA provides preliminary approval for the drug filgotinib not approved, Galapagos will now assume full responsibility for filgotinib in Europe. Gilead will pay EUR 160 million to Galapagos to accelerate commercial activities in Europe. The gap from 19 march 2019 is filled....ready for the turn up..... what do you think?
Beyond Technical Analysisfdagalapagosgapfillgilead
RonaldoH64

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.